DOAC (n=158) | VKA (n=419) | Total (n=577) | p | |
---|---|---|---|---|
Demographic data | ||||
Sex, male [n (%)] | 88 (55.7) | 239 (57.0) | 327 (56.7) | 0.771 |
Age, [median (IQR)] | 79.0 (72-83) | 79.0 (70-85) | 79.0 (71-84) | 0.774 |
Renal function | ||||
Creatinine, μmol/L [median (IQR)] | 132 (110-162) | 141 (118-193) | 138 (115-182) | 0.002 |
GFR group, [n (%)] | ||||
45-59 mL/min | 61 (38.6) | 131 (31.3) | 192 (33.3) | |
30-44 mL/min | 65 (41.1) | 147 (35.1) | 212 (36.7) | |
15-29 mL/min | 31 (19.6) | 110 (26.3) | 141 (24.4) | |
<15 mL/min | 1 (0.6) | 31 (7.4) | 32 (5.5) | 0.002 |
Comorbidity | ||||
Charlson Comorbidity Index, [median (IQR)] | 5 (4-7) | 5 (4-7) | 5 (4-7) | 0.144 |
Diabetes, [n (%)] | 45 (28.5) | 123 (29.4) | 168 (29.1) | 0.837 |
Liver insufficiency, [n (%)] | 9 (5.7) | 9 (2.1) | 18 (3.1) | 0.029 |
Arterial hypertension, [n (%)] | 109 (69.0) | 306 (73.0) | 415 (71.9) | 0.335 |
Polypharmacy, [n (%)] | 138 (87.3) | 353 (84.2) | 491 (85.1) | 0.352 |